Research article discussion
After enjoying John’s posting on the Canadian BCA/Singh case, I feel it’s time to pour some gas on the conversation, to heat things up a bit.
First, you can review the articles under consideration at the Chiropractic and Infantile Colic page. (more…)
SOURCE: Our Radiculopathy and Chiropractic Collection
Radiculopathy is characterized by motor and/or sensory changes in the neck and arms, or the legs and feet, which result from extrinsic pressure on the nerve root(s). Chiropractic is very effective in reducing that pressure on the nerve roots (oftern caused by edema), and as the nerve recovers, those down-stream symptoms abate. (more…)
Modafinil is a popular drug used by people who want or need to stay alert. It has become a popular stimulant, used by soldiers to stay awake and by citizens looking for a safe brain boost, including one in 10 researchers. The FDA issued their “Approved” stamp for it to be used for treating narcolepsy and sleep disorders in 1998. At that time, scientists claimed that it did not change levels of dopamine in those who took the drug. Increases in dopamine levels are considered a chemical signature of possible addictiveness to a drug. Since its FDA approval, modafinil is now being used “off-label” to treat depression, Parkinson’s disease and fatigue.
However, the March 2009 issue of JAMA published this study;
Volkow N, et. al., Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain., JAMA, Vol. 301, No. 11, March 18, 2009.
You can read more on this report at the Wired Science Blog.
Do you make nutritional recommendations as part of your Care Plan? Do you recommend supplements? Do you carry supplements in your office?
Many chiropractic schools only provide a 3-credit class in nutrition, so students have to continue to study on their own to develop confidence in offering recommendations. (more…)
Do you use acupuncture in your practice? If so, you may want to review our Acupuncture Section. (more…)
SOURCE: Am J Psychiatry. 2009 (Sep); 166 (9): 992-1001
This new study revealed that stimulant medications, specifically methylphenidate, are associated with a 6- to 7-times increased risk for sudden death in children and adolescents. UGH!
What does the FDA say about that? “Given the limitation of this study’s methodology, the FDA is unable to conclude that these data affect the overall risk and benefit profile of stimulant medications used to treat attention-deficit/hyperactivity.”